| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC21891 | DBCO Maleimide | DBCO Maleimide is a Click Chemistry intermidate used for antibody-drug conjugates.. |
|
| DC20355 | DBCO-NHS ester 2 | DBCO-NHS ester 2 is a derivative of DBCO (Dibenzylcyclooctyne) used in Cu-free click chemistry. |
|
| DC22076 | DBCO-NHS ester 3 | DBCO-NHS ester 3 (DIBAC-NHS) is a Click Chemistry intermidate used for antibody-drug conjugates.. |
|
| DC21987 | DBCO-PEG4 amine | DBCO-PEG4 amine (ADIBO-PEG4-amine) is a Click Chemistry intermidate used for antibody-drug conjugates.. |
|
| DC7602 | DBeQ Featured | DBeQ is a selective, potent, reversible, and ATP-competitive p97 inhibitor with IC50 of 1.5 μM. |
|
| DC12023 | dBET1 Featured | dBET1 is a potent BRD4 protein degrader based on PROTAC technology with an EC50 of 430 nM. |
|
| DC21892 | dBET23 | dBET23 is a BRD4 heterobifunctional small-molecule ligand (PROTAC), exhibits significant and selective degradation of BRD4 BD1 (DC50/5h=50 nM) in cellular degradation assays.. |
|
| DC21893 | dBET57 Featured | dBET57 is a novel BRD4 heterobifunctional small-molecule ligand (PROTAC), exhibits significant and selective degradation of BRD4 BD1 (DC50/5h=500 nM), but is inactive on BRD4 BD2.. |
|
| DC12022 | dBET6 Featured | dBET6 is a highly potent, selective and cell-permeable degrader of BET with an IC50 of 14 nM, and has antitumor activity. |
|
| DC8108 | DBPR108 | DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9. IC50 value: 15 Nm. |
|
| DC12665 | DBPR114 Featured | DBPR114 is a quinazoline-based multi-kinase inhibitor for the treatment of acute myeloid leukemia and other solid tumors. |
|
| DC7790 | CB1-IN-1(BPRCB1184) Featured | CB1-IN-1 (BPRCB1184) is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively. IC50 value: 0.3 nM (Ki, CB1R) 21 nM (Ki, CB2R) Target: CB1R in vivo: CB1-IN-1 is a novel peripherally restricted cannabinoid 1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice. CB1-IN-1 has great potential to ameliorate this related metabolic syndrome. |
|
| DC11589 | dBRD9 Featured | dBRD9 is a PROTAC that bridge the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex. |
|
| DC23976 | DC_517 | DC_05 is a potent, selective, non-nucleoside DNA methyltransferase DNMT1 inhibitor with IC50 of 1.7 uM, displays significant selectivity toward other AdoMet-dependent protein methyltransferases. |
|
| DC23977 | DC-05 Featured | DC-05 is a selective, non-nucleoside DNA methyltransferase DNMT1 inhibitor with IC50 of 10.3 uM, displays 3.6-fold selectivity over PRMT1 and >15-fold over DNMT3A, DNMT3B, G9a, SUV39H1, MLL1, SET7/9.. |
|
| DC20945 | DC_AC50 Featured | DC_AC50 (DCAC50) is a small molecule that inhibits the human copper chaperones Atox1 and CCS (Kd=6.8 and 8.2 uM), blocks copper trafficking and significantly attenuates cancer cell proliferation. |
|
| DC12361 | DC1 | DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer. |
|
| DC12055 | DC1-SMe | DC1-Sme is an antibody conjugate of phosphate prodrug of cytotoxic DNA alkylators for the targeted treatment of cancer. |
|
| DC10554 | DC260126 Featured | DC260126, a small-molecule antagonist of GPR40. |
|
| DC12554 | DC661 Featured | DC661 (DC-661) is a novel dimeric chloroquine (CQ) that is capable of deacidifying the lysosome and inhibiting autophagy significantly better than HCQ, targets palmitoyl-protein thioesterase 1 (PPT1). |
|
| DC5041 | DCC-2036 (Rebastinib) Featured | DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1/2. |
|
| DC9585 | c-Kit-IN-1(DCC-2618) Featured | DCC-2618 is a small molecule inhibitor of c-Kit and PDGFR with IC50s of 6 nM/30 nM/13 nM for c-Kit/PDGFRα/PDGFRβ respectively. |
|
| DC20175 | Ripretinib (DCC-2618) Featured | DCC-2618 is an orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and PDGFR-alpha, with IC50 values of 4 nM, 8 nM, 18 nM, 5 nM and 14 nM. |
|
| DC24137 | DCVC | DCVC (S-(1,2-dichlorovinyl)-L-cysteine) is an active metabolite of trichloroethylene. |
|
| DCAPI1304 | D-Cycloserine | D-Cycloserine |
|
| DC12593 | DD-03-171 | DD-03-171 is a small molecule, CGI1746-based BTK degrader (PROTAC, biochemical IC50=5.1 nM) that efficiently degrade C481S-BTK, exhibits enhanced anti-proliferative effects on mantle cell lymphoma (MCL) cells in vitro by degrading BTK, IKFZ1 and IKFZ3. |
|
| DC20947 | DDD 85646 Featured | DDD 85646 is a potent, specific, dual N-Myristoyltransferase NMT1/NMT2 inhibitor with IC50 of 17 nM/22 nM respectively. |
|
| DC10413 | DDP-38003 dihydrochloride | DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC50 of 84 nM. |
|
| DC10996 | DDR inhibitor X Featured | DDR inhibitor X is a potent discoidin domain receptor (DDR) inhibitor with IC50 of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.. |
|
| DC12521 | DDR1 inhibitor 2.45 | DDR1 inhibitor 2.45 (Compound 2.45) is a novel potent, selective, bioavailable Discoidin Domain Receptor 1 (DDR1) inhibitor with IC50 of 29 nM, displays 64-fold selectivity over DDR2 in biochemical assays. |
|
